natalizumab · Tysabri

Monoclonal antibody

Also known as BG00002

Biosimilars tracked: Tyruko (natalizumab-sztn)

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Sclerosis, Crohn's Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
JP
  • Prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis
Product first approved 2014PMDA
CA
  • TYSABRI (natalizumab) is indicated: • as monotherapy (i.e. single disease-modifying agent) for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis. Safety and efficacy in patients with chronic...
Product first approved 2006Health Canada
EU
  • Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant...
Product first approved 2006EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (13)
Crohn's Disease
NCT00078611 · Biogen
2004-03 – 2005-03 · Crohn's Disease
What this study did
NCT00032786 · Biogen
2002-03 – 2004-03 · Crohn's Disease
What this study did
Multiple Sclerosis
NCT04115488 · Polpharma Biologics S.A.
2019-10-01 – 2022-02-07 · Relapsing-Remitting Multiple Sclerosis (RRMS)
What this study did
NCT01416181 · Biogen
2011-09-13 – 2016-04-13 · Secondary Progressive Multiple Sclerosis
What this study did
NCT00297232 · Biogen
2006-03 – 2014-04 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT01058005 · Biogen
2010-03 – 2012-04 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT00306592 · Biogen
2006-03 – 2008-02 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT00276172 · Biogen
2003-12 – 2006-01 · Multiple Sclerosis
What this study did
NCT00030966 · Biogen
2002-01 – 2005-12 · Multiple Sclerosis, Relapsing-Remitting
What this study did
Phase 2/3 (1)
Multiple Sclerosis
NCT01440101 · Biogen
2010-11 – 2012-08 · Multiple Sclerosis
What this study did
Phase 2 (18)
Crohn's Disease
NCT00055367 · Biogen
2002-04 – 2004-05 · Crohn's Disease
What this study did
NCT00055536 · Biogen
2002-04 – 2003-07 · Crohn's Disease
What this study did
Multiple Sclerosis
NCT05418010 · Queen Mary University of London
2022-12-01 – 2027-10-31 · Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
What this study did
NCT02142192 · Biogen
2014-12-01 – 2015-06-04 · Relapsing Multiple Sclerosis
What this study did
NCT01416155 · Biogen
2010-10 – 2014-12 · Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
What this study did
NCT01405820 · Biogen
2011-08 – 2014-10 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT01077466 · Copenhagen University Hospital, Rigshospitalet
2010-03 – 2012-01 · Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
What this study did
NCT01071083 · Biogen
2010-03 – 2011-11 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT00516893 · Biogen
2006-10 – 2007-12 · Multiple Sclerosis
What this study did
NCT00097760 · Biogen
2003-06 – 2004-03 · Multiple Sclerosis, Relapsing-Remitting
What this study did
Other / comorbidity
NCT07892027 · University of Michigan Rogel Cancer Center
2026-11-10 – 2028-05-01 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT02133924 · John Levine
2016-08 – 2021-11-21 · Acute Graft Versus Host Disease
What this study did
NCT03283371 · Biogen
2018-03-20 – 2020-11-18 · Epilepsy, Focal Seizures, Partial Seizures
What this study did
NCT02176031 · Dana-Farber Cancer Institute
2015-01 – 2019-02 · Graft Versus Host Disease
What this study did
NCT02730455 · Biogen
2016-07-18 – 2017-11-20 · Acute Ischemic Stroke
What this study did
NCT01955707 · Biogen
2014-01 – 2015-04 · Acute Ischemic Stroke
What this study did
NCT00083759 · Biogen
2004-05 – 2005-02 · Rheumatoid Arthritis
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT03811886 · Case Comprehensive Cancer Center
2024-12-01 – 2026-10-01 · Pulmonary Metastatic Osteosarcoma (pOS)
What this study did
NCT00675428 · Biogen
2008-09 – 2009-12 · Multiple Myeloma
What this study did
Phase 1 (6)
Multiple Sclerosis
NCT01884935 · Biogen
2013-07 – 2014-09 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT00559702 · Biogen
2007-10 – 2011-11 · Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
What this study did
NCT00424788 · Biogen
2007-01 – 2007-10 · Relapsing Forms of Multiple Sclerosis
What this study did
Other / comorbidity
NCT05618301 · Washington University School of Medicine
2023-07-07 – 2025-06-24 · Sickle Cell Disease
What this study did
NCT03093064 · King's College London
2017-04-01 – 2023-08-07 · Schizophrenia
What this study did
NCT02483845 · Phoenix Neurological Associates, LTD
2013-05 – 2017-11 · Inclusion Body Myositis (IBM)
What this study did
Phase 4 (22)
Crohn's Disease
NCT00801125 · Biogen
2008-12 – 2010-05 · Crohn's Disease
What this study did
NCT00280956 · Biogen
2002-07 – 2004-09 · Crohn's Disease
What this study did
Multiple Sclerosis
NCT04225312 · Amsterdam UMC, location VUmc
2020-02-03 – 2025-03-01 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT02769689 · University Hospital, Clermont-Ferrand
2019-06-12 – 2024-07-20 · Multiple Sclerosis
What this study did
NCT03046251 · State University of New York at Buffalo
2015-08 – 2023-12 · Multiple Sclerosis
What this study did
NCT05177718 · Vanderbilt University Medical Center
2022-09-16 – 2023-04-05 · Multiple Sclerosis
What this study did
NCT04048577 · Berkovich, Regina MD, PhD Inc.
2019-07-03 – 2021-12-01 · Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT02904876 · University Hospital, Strasbourg, France
2015-03 – 2020-05 · Multiple Sclerosis
What this study did
NCT03516526 · Amsterdam UMC, location VUmc
2016-11-03 – 2019-07-01 · Multiple Sclerosis
What this study did
NCT02342704 · Biogen
2014-11-30 – 2016-05-18 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT02241785 · Biogen
2014-09-30 – 2016-05-02 · Relapsing Multiple Sclerosis
What this study did
NCT02325440 · University Hospital Muenster
2014-03 – 2016-04 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT02775110 · University at Buffalo
2012-11 – 2014-03 · Multiple Sclerosis
What this study did
NCT02142205 · Biogen
2012-05 – 2013-12 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT01591551 · Cornerstone Health Care, PA
2012-03 – 2013-08 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT00752778 · University Hospital, Strasbourg, France
2008-12 – 2011-03 · Multiple Sclerosis
What this study did
NCT00942214 · University Hospital, Toulouse
2009-06 – 2011-03 · Multiple Sclerosis
What this study did
NCT00771043 · Biogen
2008-11-01 – 2010-06-01 · Relapsing-remitting Multiple Sclerosis
What this study did
NCT00536120 · Biogen
2008-01 – 2009-12 · Multiple Sclerosis
What this study did
NCT00744679 · Biogen
2008-11 – 2008-12 · Multiple Sclerosis
What this study did
Early phase / not applicable (4)
Multiple Sclerosis
NCT03500328 · Johns Hopkins University
2018-05-02 – 2026-08-31 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT05172466 · Icahn School of Medicine at Mount Sinai
2022-10-31 – 2022-11-11 · Relapsing-remitting Multiple Sclerosis (RRMS)
What this study did
NCT01071512 · University of Chicago
2010-04 – 2016-01 · Multiple Sclerosis
What this study did
NCT01455220 · University of South Florida
2011-01 – 2014-10 · Multiple Sclerosis
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 4 (1)
Multiple Sclerosis
NCT01144052 · Claudio Gobbi
2010-06 – 2011-11 · Relapsing-remitting Multiple Sclerosis
What this study did
Early phase / not applicable (1)
Multiple Sclerosis
NCT01065727 · Rennes University Hospital
2010-03 – 2023-11 · Multiple Sclerosis
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Crohn's Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Natalizumab (Tysabri): this drugApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
Golimumab (Simponi)Phase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
Firategrast (SB-683699)DiscontinuedSmall moleculeVLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 10 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tysabri (natalizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2Multiple SclerosisRecruiting
Est. primary completion 2027-10-31 · NCT05418010 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 2Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2028-05-01 · NCT07892027 · CT.gov ↗
What to watch

See the full readout calendar ↗